Related Experiment Video

Updated: Sep 5, 2025

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.1K

The relationship between phosphodiesterase 4D gene polymorphism and coronary heart disease

Laixing Yan1, Ketao Li1, Weiwei Zhang2

  • 1Department of Cardiovascular Medicine, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, 310022, China. yufangdao71387@163.com.

Cellular and Molecular Biology (Noisy-Le-Grand, France)
|July 12, 2022
PubMed

Insights

This study investigated the rs918592 polymorphism in the phosphodiesterase 4D (PDE4D) gene and its association with coronary heart disease. Researchers found no significant link between this specific PDE4D gene variant and the risk of developing coronary heart disease.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Genetic Epidemiology

Background:

  • Coronary atherosclerotic heart disease poses a significant global health risk.
  • Intracellular cyclic adenosine monophosphate (cAMP) is crucial in regulating vascular smooth muscle proliferation, migration, and inflammation.
  • Phosphodiesterase 4D (PDE4D) enzyme specifically degrades cAMP, influencing cardiovascular processes.

Purpose of the Study:

  • To examine the association between phosphodiesterase 4D (PDE4D) gene polymorphism and coronary heart disease (CHD).
  • To evaluate the impact of PDE4D gene polymorphism on cardiovascular health outcomes.

Main Methods:

  • Utilized polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for genotyping.
  • Analyzed 150 participants: 50 with acute coronary syndrome (ACS) and 100 controls (NC) confirmed by coronary angiography.
  • Assessed genotype and allele frequencies of the rs918592 polymorphism in the PDE4D gene.

Main Results:

  • Genotype frequencies for AA, AG, and GG were 25.67%, 54.66%, and 22.67%, consistent with Hardy-Weinberg equilibrium (P=0.101).
  • No statistically significant differences were observed in the distribution of GG genotype (18% vs. 27%), AA+AG genotype (85% vs. 74%), or allele frequencies (G: 57% vs. 55%; A: 43% vs. 45%) between cases and controls (P<0.05).

Conclusions:

  • The rs918592 polymorphism within the PDE4D gene is not statistically associated with coronary heart disease.
  • This specific PDE4D gene variant does not appear to be a risk factor for developing coronary heart disease in the studied population.

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.0K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

33.9K

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
53
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
32
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.7K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
241
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
247